Compare Stocks: HUMA, DMAC, EDIT, and PRTC

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DMAC DiaMedica Therapeutics	$7.79 -3.1%	$7.16	$5.24 ▼ $10.42	$422.81M	0.92	200,116 shs	133,435 shs
EDIT Editas Medicine	$2.37 -3.1%	$2.84	$1.66 ▼ $4.28	$363.22M	2	2.23 million shs	722,789 shs
HUMA Humacyte	$0.44 -0.3%	$0.57	$0.34 ▼ $1.90	$121.12M	2.44	7.81 million shs	3.60 million shs
PRTC PureTech Health	$17.42	$17.42	$14.50 ▼ $19.92	$424.04M	1.15	18,480 shs	N/A

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DMAC DiaMedica Therapeutics	+4.96%	+0.37%	+23.12%	+10.14%	+14.04%
EDIT Editas Medicine	+7.49%	-14.08%	-7.22%	-18.12%	-39.90%
HUMA Humacyte	+24.12%	-1.70%	-20.32%	-33.88%	-75.17%
PRTC PureTech Health	0.00%	0.00%	0.00%	0.00%	-3.22%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DMAC DiaMedica Therapeutics	$7.79 -3.1%	$7.16	$5.24 ▼ $10.42	$422.81M	0.92	200,116 shs	133,435 shs
EDIT Editas Medicine	$2.37 -3.1%	$2.84	$1.66 ▼ $4.28	$363.22M	2	2.23 million shs	722,789 shs
HUMA Humacyte	$0.44 -0.3%	$0.57	$0.34 ▼ $1.90	$121.12M	2.44	7.81 million shs	3.60 million shs
PRTC PureTech Health	$17.42	$17.42	$14.50 ▼ $19.92	$424.04M	1.15	18,480 shs	N/A

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DMAC DiaMedica Therapeutics	+4.96%	+0.37%	+23.12%	+10.14%	+14.04%
EDIT Editas Medicine	+7.49%	-14.08%	-7.22%	-18.12%	-39.90%
HUMA Humacyte	+24.12%	-1.70%	-20.32%	-33.88%	-75.17%
PRTC PureTech Health	0.00%	0.00%	0.00%	0.00%	-3.22%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DMAC DiaMedica Therapeutics	2.60	Moderate Buy	$12.00	54.08% Upside
EDIT Editas Medicine	2.71	Moderate Buy	$5.83	146.65% Upside
HUMA Humacyte	2.63	Moderate Buy	$4.96	1,033.40% Upside
PRTC PureTech Health	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest HUMA, DMAC, EDIT, and PRTC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/16/2026	HUMA Humacyte	Williams Trading Subscribe to MarketBeat All Access to unlock brokerage rankings	Set Price Target		$1.00
10/16/2026	HUMA Humacyte	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
10/15/2026	DMAC DiaMedica Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/8/2026	EDIT Editas Medicine	Wells Fargo & Company Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Equal Weight ➝ Overweight	$4.00 ➝ $6.00
10/7/2026	HUMA Humacyte	Barclays Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold
10/6/2026	HUMA Humacyte	Barclays Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Overweight ➝ Equal Weight	$0.50
10/2/2026	HUMA Humacyte	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (E+)
9/23/2026	EDIT Editas Medicine	Guggenheim Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Neutral ➝ Buy	$5.00
8/18/2026	EDIT Editas Medicine	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$6.00
8/13/2026	HUMA Humacyte	Benchmark Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Speculative Buy	$2.00 ➝ $1.00
8/12/2026	HUMA Humacyte	BTIG Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$2.00

(Data available from 10/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DMAC DiaMedica Therapeutics	N/A	N/A	N/A	N/A	$1.08 per share	N/A
EDIT Editas Medicine	$40.52M	8.96	N/A	N/A	$0.28 per share	8.45
HUMA Humacyte	$2.12M	57.37	N/A	N/A	$0.02 per share	21.90
PRTC PureTech Health	$4.66M	91.01	N/A	N/A	$12.65 per share	1.38

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DMAC DiaMedica Therapeutics	-$32.77M	-$0.72	N/A	N/A	N/A	N/A	-77.76%	-69.43%	11/11/2026 (Estimated)
EDIT Editas Medicine	-$160.06M	-$0.75	N/A	N/A	N/A	-157.32%	-196.63%	-38.17%	11/9/2026 (Estimated)
HUMA Humacyte	-$40.83M	-$0.49	N/A	N/A	N/A	-4,556.29%	-983.32%	-88.84%	11/11/2026 (Estimated)
PRTC PureTech Health	-$109.74M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest HUMA, DMAC, EDIT, and PRTC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/11/2026	Q3 2026	DMAC DiaMedica Therapeutics	-$0.20	N/A	N/A	N/A	$13.50 million	N/A
11/11/2026	Q3 2026	HUMA Humacyte	-$0.09	N/A	N/A	N/A	$0.77 million	N/A
11/9/2026	Q3 2026	EDIT Editas Medicine	-$0.21	N/A	N/A	N/A	$4.54 million	N/A
8/12/2026	Q2 2026	HUMA Humacyte	-$0.1134	-$0.16	-$0.0466	-$0.16	$1.04 million	$0.41 million
8/10/2026	Q2 2026	DMAC DiaMedica Therapeutics	-$0.2009	-$0.19	+$0.0109	-$0.19	$13.50 million	N/A
8/5/2026	Q2 2026	EDIT Editas Medicine	-$0.2705	-$0.15	+$0.1205	-$0.15	$2.85 million	$11.89 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
DMAC DiaMedica Therapeutics	N/A	N/A	N/A	N/A	N/A
EDIT Editas Medicine	N/A	N/A	N/A	N/A	N/A
HUMA Humacyte	N/A	N/A	N/A	N/A	N/A
PRTC PureTech Health	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DMAC DiaMedica Therapeutics	N/A	6.72	6.72
EDIT Editas Medicine	N/A	3.19	3.19
HUMA Humacyte	2.07	6.21	5.74
PRTC PureTech Health	N/A	6.59	6.59

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DMAC DiaMedica Therapeutics	10.12%
EDIT Editas Medicine	71.90%
HUMA Humacyte	44.71%
PRTC PureTech Health	0.04%

Insider Ownership

Company	Insider Ownership
DMAC DiaMedica Therapeutics	5.00%
EDIT Editas Medicine	3.10%
HUMA Humacyte	3.10%
PRTC PureTech Health	5.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DMAC DiaMedica Therapeutics	35	53.93 million	51.23 million	Optionable
EDIT Editas Medicine	87	153.58 million	148.82 million	Optionable
HUMA Humacyte	184	277.80 million	269.19 million	Optionable
PRTC PureTech Health	100	24.34 million	23.05 million	Not Optionable

HUMA, DMAC, EDIT, and PRTC Headlines

Recent News About These Companies

PRTC's SPTX Presents Phase 1 GlyphAgo Data at ECNP

October 11, 2026 | markets.ft.com

PureTech Founded Entity Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of ...

October 9, 2026 | finance.yahoo.com

Tang Capital Management Boosts PureTech Health (PRTC) Stake to 7.08% After Recent Share Purchase

September 27, 2026 | kalkinemedia.comK

PureTech Health tries a lower-risk model

September 22, 2026 | investorschronicle.co.uk

PureTech Health H1 Earnings Call Highlights

September 22, 2026 | marketbeat.com

PureTech Health (PRTC) Rises After FDA Fast Track for Blood-Cancer Drug LYT-200

September 21, 2026 | asktraders.comA

PureTech Announces Successful End-of-Phase 1 Meeting with U.S. Food and Drug Administration (FDA) and Receipt of Fast Track Designation for LYT-200 in Relapsed/Refractory (R/R ...

September 21, 2026 | streetinsider.com $https://www.streetinsider.com/Business+Wire/PureTech+Announces+Successful+End-of-Phase+1+Meeting+with+U.S.+Food+and+Drug+Administration+%28FDA%29+and+Receipt+of+Fast+Track+Designation+for+LYT-200+in+RelapsedRefractory+%28RR%29+High-Risk+Myelodysplast/27082098.html$

PureTech Founded Entity Celea Therapeutics Doses First Patient in Global Phase 3 SURPASS-IPF Trial Evaluating Deupirfenidone for the Treatment of Idiopathic Pulmonary Fibrosis ...

July 13, 2026 | finance.yahoo.com

PureTech Subsidiary Celea Begins Phase 3 IPF Study Comparing Deupirfenidone With Standard Therapy (PRTC)

July 13, 2026 | uk.finance.yahoo.com

PureTech entity Celea raises $180 million to move lung disease drug into late stage trial

July 2, 2026 | reuters.com

PureTech Health plc American Depositary Shares (PRTC) Real-Time

July 1, 2026 | nasdaq.com

2 UK shares tipped to more than double my money in 2026!

June 20, 2026 | uk.finance.yahoo.com

PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers

June 9, 2026 | finance.yahoo.com

PureTech to Showcase Deupirfenidone Program at the American Thoracic Society International Conference

May 13, 2026 | businesswire.com

PureTech Health shares boosted as investee Seaport Therapeutics prices Nasdaq IPO

May 1, 2026 | proactiveinvestors.co.uk

PureTech Announces Annual Results for Year Ended December 31, 2025

April 29, 2026 | businesswire.com

PureTech Health: Notice of Results

April 13, 2026 | businesswire.com

PureTech Gains on Results

April 2, 2026 | baystreet.ca

PureTech Announces Publication of Phase 2b ELEVATE IPF Trial Results in The American Journal of Respiratory and Critical Care Medicine

April 2, 2026 | businesswire.com

PureTech Founded Entity Seaport Therapeutics Announces Publication in Science Translational Medicine Featuring GlyphAllo™ (SPT-300) as the First Triglyceride-Mimetic Prodrug to Achieve Therapeutically Relevant Drug Levels in Humans

March 25, 2026 | businesswire.com

PureTech to Present at the Leerink Partners Global Healthcare Conference

February 25, 2026 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

HUMA, DMAC, EDIT, and PRTC Company Descriptions

DiaMedica Therapeutics NASDAQ:DMAC

$7.79 -0.25 (-3.13%)

As of 01:25 PM Eastern

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Editas Medicine NASDAQ:EDIT

$2.37 -0.08 (-3.07%)

As of 01:25 PM Eastern

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Humacyte NASDAQ:HUMA

$0.44 0.00 (-0.34%)

As of 01:25 PM Eastern

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.

PureTech Health NASDAQ:PRTC

$17.42 0.00 (0.00%)

As of 10/15/2026

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest HUMA, DMAC, EDIT, and PRTC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest HUMA, DMAC, EDIT, and PRTC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

HUMA, DMAC, EDIT, and PRTC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

HUMA, DMAC, EDIT, and PRTC Company Descriptions

DiaMedica Therapeutics NASDAQ:DMAC

Editas Medicine NASDAQ:EDIT

Humacyte NASDAQ:HUMA

PureTech Health NASDAQ:PRTC

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest HUMA, DMAC, EDIT, and PRTC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest HUMA, DMAC, EDIT, and PRTC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

HUMA, DMAC, EDIT, and PRTC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

HUMA, DMAC, EDIT, and PRTC Company Descriptions

DiaMedica Therapeutics NASDAQ:DMAC

Editas Medicine NASDAQ:EDIT

Humacyte NASDAQ:HUMA

PureTech Health NASDAQ:PRTC

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools